Prime Medicine, Inc. (PRME)

Prime Medicine Stock Forecast

Stock Price Forecast

The 4 analysts that cover Prime Medicine stock have a consensus rating of "Buy" and an average price target of $7.56, which forecasts a 114.16% increase in the stock price over the next year. The lowest target is $4.25 and the highest is $11.

Price Target: $7.56 (+114.16%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$4.25	$7.56	$9.00	$11
Change	+20.40%	+114.16%	+154.96%	+211.61%

Analyst Ratings

The average analyst rating for Prime Medicine stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Oct '25	Nov '25	Dec '25	Jan '26	Feb '26	Mar '26
Strong Buy	2	2	2	2	2	1
Buy	1	1	1	1	1	2
Hold	3	3	3	3	3	3
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	6	6	6	6	6	6

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Kostas Biliouris Oppenheimer	Oppenheimer	Buy Initiates $11	Buy	Initiates	$11	+211.61%	Mar 12, 2026
Samantha Semenkow Citigroup	Citigroup	Hold Maintains $5 → $4.25	Hold	Maintains	$5 → $4.25	+20.40%	Nov 11, 2025
Geulah Livshits Chardan Capital	Chardan Capital	Strong Buy Maintains $10 → $9	Strong Buy	Maintains	$10 → $9	+154.96%	Nov 10, 2025
Samantha Semenkow Citigroup	Citigroup	Hold Maintains $1.5 → $4	Hold	Maintains	$1.5 → $4	+13.31%	Aug 12, 2025
Geulah Livshits Chardan Capital	Chardan Capital	Strong Buy Maintains $12 → $10	Strong Buy	Maintains	$12 → $10	+183.29%	Aug 8, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

5.34M

Increased by 15.20%

from 4.63M

Revenue Next Year

22.21M

Increased by 316.23%

from 5.34M

EPS This Year

-0.96

from -1.35

EPS Next Year

-0.89

from -0.96

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	-	-	-	2.98M	4.63M	5.34M	22.21M
Revenue Growth	-	-	-	-	55.28%	15.20%	316.23%
EPS	-14.19	-4.19	-2.18	-1.65	-1.35	-0.96	-0.89
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	14	13

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027	2028	2029	2030
High	10.5M	141.8M
Avg	5.3M	22.2M
Low	n/a	n/a

Revenue Growth

Revenue Growth	2026	2027	2028	2029	2030
High	126.7%	2,556.5%
Avg	15.2%	316.2%
Low	-	-

EPS Forecast

EPS	2026	2027	2028	2029	2030
High	-0.59	-0.37
Avg	-0.96	-0.89
Low	-1.36	-1.37

EPS Growth

EPS Growth	2026	2027	2028	2029	2030
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.